Interim report, May–July 2021/22

Market recovery with short-term cost challenges

The market continued to recover with stronger demand and better access to customers particularly in more mature markets. Orders grew by double digits, when excluding Elekta’s largest order ever in the first quarter last year. Installation volumes increased and revenue grew in line with pre-pandemic levels. We are experiencing temporary headwinds to our gross margin due to increased supply-chain, logistics and service costs.

Gustaf Salford
President and CEO

First quarter

• Gross order intake amounted to SEK 3,980 M (4,451), corresponding to a 4 percent decrease in constant currency. When excluding last year’s effect of Elekta’s largest order ever, order intake had a growth of 17 percent
• Net sales were SEK 3,009 M (2,981), corresponding to an 8 percent growth in constant currency
• Gross margin amounted to 37.1 percent (45.9), mainly due to higher supply-chain and logistics costs
• EBIT amounted to SEK 201 M (335), corresponding to an EBIT margin of 6.7 percent (11.2)
• Earnings per share was SEK 0.33 (0.57) before/after dilution
• Cash flow after continuous investments decreased by SEK 371 M to SEK -343 M (26), mainly related to lower earnings, increased R&D investments and increased working capital
• At today’s AGM the Board of Directors proposes a dividend of SEK 2.20 (1.80) per share (paid in two instalments) for the fiscal year 2020/21. This corresponds to 67 percent (63) of the net profit for the fiscal year 2020/21

¹ After continuous investments.
² Before/after dilution.
³ Based on constant currency.
⁴ Compared to last rolling twelve months period Aug 2019 – Jul 2020 based on constant currency.

# # #
 

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: [email protected]
Time zone: CET: Central European Time

Johan Adebäck, CFO, Elekta AB (publ)
Tel: +46 70 873 33 21, e-mail: [email protected]
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on August 25, 2021. (REGMAR) 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.